You need to enable JavaScript to run this app.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated
Cookie Policy
Yes, I accept cookies
Steering Committee
About Us
Newsletter
Contact
Visit:
Steering Committee
About Us
Newsletter
Contact
Types
Therapeutics
Congresses
Trials
Expert Opinions
ASH 2020
AML Types
Signaling pathway mutations
Epigenetic modifier mutations
Origin
Chromosomal aberrations
Nucleophosmin mutations
Tumor suppressor mutations
Spliceosome mutations
Transcription factor mutations
Cohesin mutations
View all Types
Gert Ossenkoppele
Executive Steering Committee Member
Gert Ossenkoppele
Executive Steering Committee Member
Types
ASXL1
Core binding factor
DNMT3A
FLT3-ITD
FLT3-TKD
IDH1
IDH2
NPM1
Promyelocytic leukemia
RUNX1
TET2
TP53
Interventions
Allo-HSCT
Azacitidine
CC-486
Chemotherapy
CPX-351
Crenolanib
Cytarabine
Enasidenib
Gemtuzumab ozogamicin
Gilteritinib
Hypomethylating agents
Ivosidenib
Midostaurin
Pracinostat
Quizartinib
Ruxolitinib
Sunitinib
Tacrolimus
Tandutinib
Venetoclax
Events
ASH 2016
ASH 2017
ASH 2018
ASH 2019
EHA 2017
EHA 2018
EHA 2019
ESH 2018
ISAL 2019
MRD Symposium
NCRI AML Academy 2019
Trials
ADMIRAL
AMADEUS
AML17
E2906
FLUGAZA
NCT02287233
QuANTUM-R
RATIFY
VIOLA
All
|
12 Articles
|
15 Videos
|
0 Podcasts